Anandamide’s supplier runs trials and publishes findings so practitioners can prescribe with confidence.
The flagship dewaxed extract (product code IPV4000) is part of in-vitro studies on toxicity, cytotoxicity and mutagenic effects against breast-cancer cell lines, conducted at the Jawaharlal Nehru Cancer Hospital & Research Centre, with work published in international journals.
Disease-specific guidance draws on the WHO Expert Committee on Drug Dependence reviews of cannabinoids (2017–18), alongside peer-reviewed work on neuropathic pain, chemotherapy-induced nausea and MS-related spasticity.
In palliative settings, cannabinoid-based medicine is explored two ways: as an adjuvant alongside established protocols, and as an option where conventional treatments have not worked. Doctors decide on a case-by-case basis using their own clinical judgement.
Send your condition or an existing prescription. A guide will walk you through options, dosing and the consultation process — no obligation.
